The field of oncology has witnessed a paradigm shift in recent years with the rise of antibody-drug conjugates (ADCs). These sophisticated therapies combine the precision of monoclonal antibodies with the cytotoxic powerRead More…
The field of antibody-drug conjugates (ADCs) is experiencing a major transformation due to the development of bispecific ADCs (BsADCs) that merge the dual-targeting functionality of bispecific antibodies (BsAbs) with the cell-killing powerRead More…
CD33 CD33, a 67kda transmembrane glycoprotein receptor, is usually expressed in normal myeloid cells and it is the target of GO because it is preferentially overexpressed in AML cells. The intracellular immunoreceptorRead More…
Breast cancer is the most common cancer among women. In 2020, breast cancer has replaced lung cancer as the number one cancer in the world. The latest global cancer burden data forRead More…
ADC drugs are undoubtedly the focus of many pharmaceutical companies competing for layout in 2020, reaching $40 billion deal in less than a year. AstraZeneca built a partnership with the Daiichi SankyoRead More…
On September 13, 2020, Gilead announced that it would acquire Immunomedics, whose core product is Trop-2 ADC drug Trodelvy, for more than $20 billion. On September 14, 2020, Merck Sharp & DohmeRead More…
The United States FDA approved the extended indication of its antibody coupling drug Kadcyla (ado-trastuzumab emtansine) as a postoperative adjunctive therapy for early mammary cancer patients with positive HER2 and still residualRead More…
Breast cancer is the most common cancer and cause of death among women. About 20% of breast cancers are HER2-positive (IHC3+ or IHC2+/ISH+), and the remaining 80% are HER2-negative. HER2 is aRead More…